Agios Pharma stock analysis
Agios Pharma (0HB0) Share Price & Analysis
0HB0 Stock Chart & Stats
- Day’s Range
- $29.54 - $30.56
- 52-Week Range
- $22.40 - $45.81
- Previous Close
- $30.56
- Volume
- N/A
- Average Volume (3M)
- 489
- Market Cap
- $1.79B
- Enterprise Value
- $1.38B
- Total Cash (Recent Filing)
- $630.01M
- Total Debt (Recent Filing)
- $26.53M
- Price to Earnings (P/E)
- ―
- Beta
- 1.70
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -1.11
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Commercial Revenue Growth
The sharp increase in quarterly revenue shows meaningful commercial traction for AQVESME and expanding product adoption. If prescription growth and persistence continue, the launch can create a stronger recurring revenue base and improve operating leverage over the next several quarters.
Strong Product Persistence And Market Access
High patient persistence supports recurring product revenue and suggests the therapy is delivering durable value after initiation. Broad payer coverage also reduces access friction, helping the company convert prescriptions into sustained treatment and supporting longer-term launch economics.
Financial Flexibility From Cash And Low Leverage
A substantial cash reserve combined with minimal leverage gives Agios capacity to fund commercial expansion, clinical development, and potential launches without near-term dependence on heavy borrowing. This financial flexibility supports execution while management works toward profitability.
Bears Say
Persistent Losses And Cash Burn
Large ongoing losses and negative free cash flow mean the business is not yet self-funding despite accelerating revenue. Continued cash consumption could reduce financial flexibility over time and may require operating improvement or additional financing before profitability is reached.
Regulatory Uncertainty For Sickle Cell Launch
The extended FDA review delays potential sickle cell commercialization and leaves launch timing dependent on additional regulatory work. A required REMS could also add prescribing, education, or monitoring requirements, potentially increasing adoption friction and launch costs.
Elevated Commercial Operating Expenses
Higher selling and administrative spending is placing pressure on near-term profitability as Agios builds commercial infrastructure and supports multiple launches. Revenue growth will need to outpace these costs for the company to achieve sustainable operating leverage and its profitability target.
Agios Pharma News
0HB0 FAQ
What was Agios Pharma’s price range in the past 12 months?
What is Agios Pharma’s market cap?
When is Agios Pharma’s upcoming earnings report date?
How were Agios Pharma’s earnings last quarter?
Is Agios Pharma overvalued?
Does Agios Pharma pay dividends?
What is Agios Pharma’s EPS estimate?
How many shares outstanding does Agios Pharma have?
What happened to Agios Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Agios Pharma?
What is the TipRanks Smart Score and how is it calculated?
Agios Pharma Stock Smart Score
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Goff
- Employees
- 540
- Website
- www.agios.com
- Address
- 88 Sidney Street, Cambridge, MA, 02139, US
Agios Pharma (0HB0) Earnings & Revenues
0HB0 Company Deck
0HB0 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Agios reported record revenue, rapid AQVESME launch adoption, 75% six-month persistence, international growth, a strong cash position, readiness for a potential sickle cell launch, and encouraging pipeline data. The main challenges were the three-month FDA review extension and uncertainty around a potential REMS, along with higher SG&A, a continuing net loss, and a planned one-time headcount reduction charge.
View all GB:0HB0 earnings summaries0HB0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |










